Company news

Filament Health Corp news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Filament Health announces interim results from phase i clinical trial at the university of california san francisco

May 30, 2023

Filament Health announces first ever Nagoya Protocol-compliant shipment of iboga from Gabon

May 17, 2023

Filament Health announces first quarter 2023 financial results and operational highlights

May 12, 2023

Filament Health to host virtual investor update

May 8, 2023

Filament Health announces spring 2023 event and media appearances

April 25, 2023

Filament Health and PharmAla biotech announce release of GMP MDMA capsules

April 11, 2023

Filament Health reports Q4 and year end 2022 financial results and operational highlights

March 31, 2023

Filament Health announces FDA approval of phase ii clinical trial studying psilocybin for methamphetamine use disorder

March 15, 2023

Filament Health announces second psilocybin supply agreement with the centre for addiction and Mental Health

February 14, 2023

Filament Health announces clinical trial approval in partnership with Psychiatric Centre Copenhagen

January 18, 2023

Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses

January 10, 2023

Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses

January 10, 2023

Filament Health announces CEO year end letter and change to board of directors

December 30, 2022

Filament Health and psyence announce worldwide licensing agreement of psilocybin capsule for palliative care

December 15, 2022

Filament Health announces new united states patent issuances

November 30, 2022

Filament Health announces psilocybin supply agreement with the centre for addiction and mental health

November 17, 2022

Filament Health announces third quarter 2022 financial results and operational highlights

November 10, 2022

Filament Health to host virtual investor update

October 12, 2022

Filament Health and ATMA journey centers announce 14 subjects dosed in health canada-approved psilocybin clinical trial

September 1, 2022

Filament Health appoints new members to board of directors and advisory council

August 24, 2022

Filament Health announces eighth patent issuance

August 17, 2022

Filament Health announces second quarter 2022 financial results and Operational Highlights

August 15, 2022

Filament Health announces participation in Project Solace

July 28, 2022

Filament Health announces closing of $2,500,080 private placement

July 13, 2022

Filament Health issued third patent by United States Patent and trademark office

July 12, 2022

Filament Health announces first dosing in groundbreaking FDA-approved psilocin clinical trial

July 7, 2022

Filament Health announces sixth patent issuance

July 6, 2022

Filament Health announces private placement of units and convertible debenture units of up to $2,500,000

June 30, 2022

Filament Health announces annual general meeting voting results

June 28, 2022

Filament Health announces patient dosing through health canada special access program

June 16, 2022

Filament Health cultivates 70th psychedelic mushroom variety and announces annual general meeting

June 10, 2022

Filament Health and Jaguar Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications

June 9, 2022

Filament Health is issued second patent by United States Patent and Trademark Office and reports Q1 results

May 17, 2022

Filament Health announces fourth patent issuance

April 27, 2022

Filament Health and psyence enter into exclusive licensing agreement for natural psilocybin products

April 19, 2022

Filament Health is issued patent by united states patent and trademark office

April 13, 2022

Filament Health announces pre-ind meeting with united states food and drug administration

April 12, 2022

Filament Health to participate in prominent psychedelic investor conferences in April 2022

April 7, 2022

Filament Health reports Q4 and year end 2021 financial results and operational highlights

March 31, 2022

Filament Health announces second patent issuance

March 23, 2022

Filament Health to Participate in the 34th Annual Roth Conference

March 8, 2022

Filament Health and ATMA Journey Centers Announce Licensing Agreement

February 23, 2022

Filament Health refiles Q2 and Q3 interim financial statements and MD&A

February 22, 2022

Filament Health and Cybin Therapeutics announce approval for phase ii clinical trial for depression

January 31, 2022

Filament Health Subsidiary Psilo Scientific Announces Inclusion in Health Canada List of Licensed Psilocybin Producers

January 26, 2022

Filament Health and Cybin Therapeutics announce licensing agreement

January 14, 2022

Filament Health recognizes the restoration of access to restricted drugs via the Health Canada special access program

January 5, 2022

Filament Health announces health canada approval for phase ii trial administering new psilocybin microdose formulation

January 4, 2022

Filament Health to Participate in Key Psychedelics Conferences in December 2021

December 1, 2021

Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights

November 15, 2021

← Newer news releases · Older news releases →

Decks